SCHEMBL972770

SCHEMBL972770

CC(=O)OC(=O)[C@@H](N)CCC(N)=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
ALOX15 P16050 1/20 0.52
BLM P54132 1/20 0.52
PMP22 Q01453 1/20 0.52
DPP4 P27487 1/20 0.42
DPP8 Q6V1X1 1/20 0.42
DPP9 Q86TI2 1/20 0.42
ALDH1A1 P00352 2/20 0.35
TSHR P16473 2/20 0.35
CYP1A2 P05177 2/20 0.34
GRM8 O00222 1/20 0.34
GRM6 O15303 1/20 0.34
GRIN2D O15399 1/20 0.34
GRIN3B O60391 1/20 0.34
GSR P00390 1/20 0.34
GRIK1 P39086 1/20 0.34
GRM5 P41594 1/20 0.34
GRIA1 P42261 1/20 0.34
GRIA2 P42262 1/20 0.34
GRIA3 P42263 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28818337 1.00 KMT2A (0.52) KMT2AALOX15BLMPMP22DPP4
SCHEMBL711607 0.87 ALOX15 (0.60) KMT2AALOX15BLMPMP22DPP4
SCHEMBL28313344 0.87 ALOX15 (0.60) KMT2AALOX15BLMPMP22DPP4
SCHEMBL1237866 0.85 ALOX15 (0.48) KMT2AALOX15BLMPMP22DPP4
SCHEMBL23200441 0.84 CYP1A2 (0.54) KMT2AALOX15BLMPMP22DPP4
SCHEMBL1606668 0.84 SLC1A1 (0.36) KMT2AALOX15BLMPMP22ALDH1A1
SCHEMBL8838342 0.84 CYP1A2 (0.54) KMT2AALOX15BLMPMP22DPP4
SCHEMBL8128271 0.84 SLC1A1 (0.36) KMT2AALOX15BLMPMP22ALDH1A1
SCHEMBL8838340 0.84 SLC1A1 (0.36) KMT2AALOX15BLMPMP22ALDH1A1
SCHEMBL7176759 0.83 ALOX15 (0.56) KMT2AALOX15BLMPMP22DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087109-A1 PERSONAL CARE COMPOSITION BASED ON AN ACETYL AMINOACID COMPOUND AND A CYSTINE COMPOUND UNILEVER IP HOLDINGS B.V. (NL) 2026-04-30 WO claimed
US-20260060912-A1 SKIN CARE PRODUCT WITH PROTEIN MATRIX Eighth Day Labs, LLC (US) 2026-03-05 US claimed
US-12496266-B2 Skin care product with protein matrix Eighth Day Labs, LLC (US) 2025-12-16 US claimed
US-20250152499-A1 COMPOSITIONS AND METHODS FOR SUPPORTING SKIN BARRIER HOMEOSTASIS Skinfix Inc. (CA) 2025-05-15 US claimed
US-20250090443-A1 SKIN CARE COMPOSITIONS AND THEIR USES Flawless Beauty LLC 2025-03-20 US claimed
US-12201717-B2 Compositions and methods for supporting skin barrier homeostasis Skinfix Inc. (CA) 2025-01-21 US claimed
US-20240245596-A1 SKIN CARE PRODUCT WITH PROTEIN MATRIX Eighth Day Labs, LLC (US) 2024-07-25 US claimed
WO-2024098078-A2 COMPOSITIONS AND METHODS FOR SUPPORTING SKIN BARRIER HOMEOSTASIS Skinfix Inc. (CA) 2024-05-10 WO claimed
US-20240139095-A1 COMPOSITIONS AND METHODS FOR SUPPORTING SKIN BARRIER HOMEOSTASIS Skinfix Inc. (CA) 2024-05-02 US claimed
CN-117860601-A Application of glutaminyl ethyl indole, restorative and skin care product and cosmetic 熬夜肌实验室系统工程(上海)有限公司 2024-04-12 CN claimed
CN-107582521-A Good acetyl glutamine injection of a kind of stability and preparation method thereof 江西省子轩科技有限公司 2018-01-16 CN claimed
CN-105037195-A Aceglutamide, and injection and preparation method thereof KAMP PHARMACEUTICALS CO LTD 2015-11-11 CN claimed
CN-102018668-B Preparation method of aceglutamide SHANGHAI ZHAOHUI PHARMACEUTICAL CO LTD 2012-01-18 CN claimed
CN-102018668-A Preparation method of aceglutamide SHANGHAI ZHAOHUI PHARMACEUTICAL CO LTD 2011-04-20 CN claimed
US-20110020251-A1 Ultraviolet-Absorbing Compounds AVOCA LLC 2011-01-27 US claimed
CN-1830425-A Preparation method of acetyl glutamine injection BALIMOER PHARMACEUTICAL TONGHU (CN) 2006-09-13 CN claimed
CN-1444931-A Aceglutamide injection ZHANG SONG (CN) 2003-10-01 CN claimed
EP-0957887-A2 COMPOSITION AND METHOD FOR REDUCING STINGING IN SKIN E-L Management Corp. (US) 1999-11-24 EP claimed
WO-1999013819-A2 COMPOSITION AND METHOD FOR REDUCING STINGING IN SKIN E-L MANAGEMENT CORP. (US) 1999-03-25 WO claimed
WO-1995026744-A1 TUMOR NECROSIS FACTOR INHIBITORS CENTOCOR, INC. (US) 1995-10-12 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060912-A1 SKIN CARE PRODUCT WITH PROTEIN MATRIX CUTA, HGFAC, BHMT KMT2A 4458/4885ALOX15 2800/4885BLM 4671/4885
US-20110020251-A1 Ultraviolet-Absorbing Compounds UFM1, UHRF1, CUTA KMT2A 756/4885ALOX15 2795/4885BLM 799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.